FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157199750> ?p ?o ?g. }

• W2157199750 endingPage "680" @default.
• W2157199750 startingPage "673" @default.
• W2157199750 abstract "Intravenous immunoglobulin (IVIg) treatment ameliorates the course of Guillain-Barré syndrome (GBS), but its specific mode of action is unknown. We attempted to delineate the effect of IVIg on neuromuscular blocking antibodies in GBS. A total of seven GBS serum samples were examined for blocking antibodies and the effect of IVIg with a macro-patch-clamp technique in mouse hemidiaphragms. First, serum was tested before and after treatment with IVIg. Second, we investigated with coincubation experiments whether the IVIg was capable of neutralizing neuromuscular blocking antibodies in GBS serum or affinity-purified immunoglobulin G (IgG) fractions. Finally, the mechanism of the neutralizing effect was studied by the coincubation of active blocking GBS IgG with Fab and Fc fragments prepared from IVIg. All GBS sera (two adults and two children) and GBS IgG fractions (three adults) taken before treatment with IVIg blocked evoked quantal release by approximately 90%. Blocking activity was markedly reduced in sera obtained after treatment with IVIg. Coincubation of the pretreatment blocking serum with the posttreatment serum, or with the IVIg preparation used for treatment, reduced the blocking activity of the pretreatment GBS serum. When GBS IgG was coincubated with IVIg, the blocking activity of GBS IgG was diminished dose-dependently. Monovalent and divalent Fab fragments prepared from the IVIg were as effective as whole IVIg, but Fc fragments were ineffective. Therapeutic IVIg is capable of neutralizing neuromuscular blocking antibodies in GBS by a dose-dependent, antibody-mediated mechanism. This may, in part, explain its therapeutic efficacy." @default.
• W2157199750 created "2016-06-24" @default.
• W2157199750 creator A5005446755 @default.
• W2157199750 creator A5027976216 @default.
• W2157199750 creator A5059502423 @default.
• W2157199750 creator A5071012492 @default.
• W2157199750 date "2002-05-03" @default.
• W2157199750 modified "2023-09-29" @default.
• W2157199750 title "Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome" @default.
• W2157199750 cites W1501694000 @default.
• W2157199750 cites W1968536817 @default.
• W2157199750 cites W1969582209 @default.
• W2157199750 cites W1971868683 @default.
• W2157199750 cites W1977282646 @default.
• W2157199750 cites W1984098270 @default.
• W2157199750 cites W1991027093 @default.
• W2157199750 cites W1995199378 @default.
• W2157199750 cites W1999463245 @default.
• W2157199750 cites W2003149280 @default.
• W2157199750 cites W2003582797 @default.
• W2157199750 cites W2008249012 @default.
• W2157199750 cites W2022258023 @default.
• W2157199750 cites W2039788052 @default.
• W2157199750 cites W2047056828 @default.
• W2157199750 cites W2051331250 @default.
• W2157199750 cites W2057477246 @default.
• W2157199750 cites W2060056853 @default.
• W2157199750 cites W2063109954 @default.
• W2157199750 cites W2064640622 @default.
• W2157199750 cites W2066833307 @default.
• W2157199750 cites W2068001029 @default.
• W2157199750 cites W2071312755 @default.
• W2157199750 cites W2072852217 @default.
• W2157199750 cites W2073714591 @default.
• W2157199750 cites W2073950563 @default.
• W2157199750 cites W2091352495 @default.
• W2157199750 cites W2093602775 @default.
• W2157199750 cites W2095788709 @default.
• W2157199750 cites W2102130434 @default.
• W2157199750 cites W2163550872 @default.
• W2157199750 cites W2318959418 @default.
• W2157199750 cites W2417717190 @default.
• W2157199750 cites W4231768803 @default.
• W2157199750 cites W4322388498 @default.
• W2157199750 doi "https://doi.org/10.1002/ana.10205" @default.
• W2157199750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12112071" @default.
• W2157199750 hasPublicationYear "2002" @default.
• W2157199750 type Work @default.
• W2157199750 sameAs 2157199750 @default.
• W2157199750 citedByCount "132" @default.
• W2157199750 countsByYear W21571997502012 @default.
• W2157199750 countsByYear W21571997502013 @default.
• W2157199750 countsByYear W21571997502014 @default.
• W2157199750 countsByYear W21571997502015 @default.
• W2157199750 countsByYear W21571997502016 @default.
• W2157199750 countsByYear W21571997502017 @default.
• W2157199750 countsByYear W21571997502018 @default.
• W2157199750 countsByYear W21571997502019 @default.
• W2157199750 countsByYear W21571997502020 @default.
• W2157199750 countsByYear W21571997502021 @default.
• W2157199750 countsByYear W21571997502022 @default.
• W2157199750 crossrefType "journal-article" @default.
• W2157199750 hasAuthorship W2157199750A5005446755 @default.
• W2157199750 hasAuthorship W2157199750A5027976216 @default.
• W2157199750 hasAuthorship W2157199750A5059502423 @default.
• W2157199750 hasAuthorship W2157199750A5071012492 @default.
• W2157199750 hasConcept C105795698 @default.
• W2157199750 hasConcept C144745244 @default.
• W2157199750 hasConcept C159654299 @default.
• W2157199750 hasConcept C203014093 @default.
• W2157199750 hasConcept C2778691916 @default.
• W2157199750 hasConcept C2779261636 @default.
• W2157199750 hasConcept C2780898057 @default.
• W2157199750 hasConcept C33923547 @default.
• W2157199750 hasConcept C45121317 @default.
• W2157199750 hasConcept C71924100 @default.
• W2157199750 hasConcept C98274493 @default.
• W2157199750 hasConceptScore W2157199750C105795698 @default.
• W2157199750 hasConceptScore W2157199750C144745244 @default.
• W2157199750 hasConceptScore W2157199750C159654299 @default.
• W2157199750 hasConceptScore W2157199750C203014093 @default.
• W2157199750 hasConceptScore W2157199750C2778691916 @default.
• W2157199750 hasConceptScore W2157199750C2779261636 @default.
• W2157199750 hasConceptScore W2157199750C2780898057 @default.
• W2157199750 hasConceptScore W2157199750C33923547 @default.
• W2157199750 hasConceptScore W2157199750C45121317 @default.
• W2157199750 hasConceptScore W2157199750C71924100 @default.
• W2157199750 hasConceptScore W2157199750C98274493 @default.
• W2157199750 hasFunder F4320320879 @default.
• W2157199750 hasIssue "6" @default.
• W2157199750 hasLocation W21571997501 @default.
• W2157199750 hasLocation W21571997502 @default.
• W2157199750 hasOpenAccess W2157199750 @default.
• W2157199750 hasPrimaryLocation W21571997501 @default.
• W2157199750 hasRelatedWork W119962168 @default.
• W2157199750 hasRelatedWork W1993238250 @default.
• W2157199750 hasRelatedWork W2067890699 @default.
• W2157199750 hasRelatedWork W2072415202 @default.

• next